nach oben

Journal of Neuro-Oncology

Erschienen in:

31.03.2020 | Laboratory Investigation

In silico analysis of the immunological landscape of pituitary adenomas

verfasst von: Jacky T. Yeung, Matthew D. Vesely, Danielle F. Miyagishima

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Immunotherapy has gained traction in the treatment of solid tumors but the immunological landscape of pituitary adenomas is not well defined. We sought to investigate the immunological composition in pituitary adenomas using RNA deconvolution (CIBERSORTx) on an existing gene expression dataset for pituitary adenomas.

Methods

We applied an established computational approach (CIBERSORTx) on 134 pituitary adenomas from a previously published gene expression dataset to infer the proportions of 22 subsets of immune cells. We investigated associations between each immune cell type and tumor subtype.

Results

We found that the majority of infiltrating immune cells within pituitary adenomas were comprised of M2 macrophages followed by resting CD4⁺ memory T cells and mast cells. Silent pituitary tumors have higher M2 macrophage fractions when compared to other subtypes. In contrast, Cushing pituitary tumors, both overt and subclinical cases, had higher CD8⁺ T cells fractions than GH tumors, prolactinomas, hyperthyroid tumors, and silent tumors.

Conclusions

RNA deconvolution of the immune infiltrates of pituitary adenomas using CIBERSORTx suggests that most pituitary adenomas comprise of M2 macrophages, but each adenoma subtype has a unique immune landscape. This may have implications in targeting each adenoma subtype with different immunotherapies.

Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2016) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro Oncol 18(5):1–75. https://doi.org/10.1093/neuonc/now207 CrossRef

Chen L, Han X (2015) Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125(9):3384–3391. https://doi.org/10.1172/JCI80011 CrossRefPubMedPubMedCentral

Lu JQ, Adam B, Jack AS, Lam A, Broad RW, Chik CL (2015) Immune cell infiltrates in pituitary adenomas: more macrophages in larger adenomas and more T cells in growth hormone adenomas. Endocr Pathol 26(3):263–272. https://doi.org/10.1007/s12022-015-9383-6 CrossRefPubMed

Mei Y, Bi WL, Greenwald NF, Du Z, Agar NY, Kaiser UB, Woodmansee WW, Reardon DA, Freeman GJ, Fecci PE, Laws ER Jr, Santagata S, Dunn GP, Dunn IF (2016) Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget 7(47):76565–76576. https://doi.org/10.18632/oncotarget.12088 CrossRefPubMedPubMedCentral

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12(5):453–457. https://doi.org/10.1038/nmeth.3337 CrossRefPubMedPubMedCentral

Athar A, Fullgrabe A, George N, Iqbal H, Huerta L, Ali A, Snow C, Fonseca NA, Petryszak R, Papatheodorou I, Sarkans U, Brazma A (2019) ArrayExpress update—from bulk to single-cell expression data. Nucleic Acids Res 47(D1):D711–D715. https://doi.org/10.1093/nar/gky964 CrossRefPubMed

Neou M, Villa C, Armignacco R, Jouinot A, RaffinSanson ML, Septier A, Letourneur F, Diry S, Diedisheim M, Izac B, Gaspar C, Perlemoine K, Verjus V, Bernier M, Boulin A, Emile JF, Bertagna X, Jaffrezic F, Laloe D, Baussart B, Bertherat J, Gaillard S, Assie G (2020) Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell 37(1):123–134. https://doi.org/10.1016/j.ccell.2019.11.002 CrossRefPubMed

Marques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Dorward N, Grieve J, Mendoza N, Muquit S, Grossman AB, Balkwill F, Korbonits M (2019) Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. Acta Neuropathol Commun 7(1):172. https://doi.org/10.1186/s40478-019-0830-3 CrossRefPubMedPubMedCentral

Sato M, Tamura R, Tamura H, Mase T, Kosugi K, Morimoto Y, Yoshida K, Toda M (2019) Analysis of Tumor Angiogenesis and Immune Microenvironment in NonFunctional Pituitary Endocrine Tumors. J Clin Med 8(5):695. https://doi.org/10.3390/jcm8050695 CrossRefPubMedCentral

10.

Yagnik G, Rutowski MJ, Shah SS, Aghi MK (2019) Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes. Oncotarget 10(22):2212–2223. https://doi.org/10.18632/oncotarget.26775 CrossRefPubMedPubMedCentral

11.

Barry S, Carlsen E, Marques P, Stiles CE, Gadaleta E, Berney DM, Roncaroli F, Chelala C, Solomou A, Herincs M, Caimari F, Grossman AB, Crnogorac-Jurcevic T, Haworth O, Gaston-Massuet C, Korbonits M (2019) Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors. Oncogene 38(27):5381–5395. https://doi.org/10.1038/s41388-019-0779-5 CrossRefPubMedPubMedCentral

12.

Kemeny HR, Elsamadicy AA, Farber SH, Champion CD, Lorrey SJ, Chongsathidkiet P, Woroniecka KI, Cui X, Shen SH, Rhodin KE, Tsvankin V, Everitt J, Sanchez-Perez L, Healy P, McLendon RE, Codd PJ, Dunn IF, Fecci PE (2020) Targeting PD-L1 initiates effective antitumor immunity in a murine model of cushing disease. Clin Cancer Res 26(5):1141–1151. https://doi.org/10.1158/1078-0432.CCR-18-3486 CrossRefPubMed

13.

Wang PF, Wang TJ, Yang YK, Yao K, Li Z, Li YM, Yan CX (2018) The expression profile of PD-L1 and CD8(+) lymphocyte in pituitary adenomas indicating for immunotherapy. J Neurooncol 139(1):89–95. https://doi.org/10.1007/s11060-018-2844-2 CrossRefPubMed

14.

Zhang Y, Chen L (2016) Classification of advanced human cancers based on tumor immunity in the microenvironment (TIME) for cancer immunotherapy. JAMA Oncol 2(11):1403–1404. https://doi.org/10.1001/jamaoncol.2016.2450 CrossRefPubMedPubMedCentral

15.

Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA (2018) Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol 1711:243–259. https://doi.org/10.1007/978-1-4939-7493-1_12 CrossRefPubMedPubMedCentral

16.

Rohr-Udilova N, Klinglmuller F, Schulte-Hermann R, Stift J, Herac M, Salzmann M, Finotello F, Timelthaler G, Oberhuber G, Pinter M, Reiberger T, Jensen-Jarolim E, Eferl R, Trauner M (2018) Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. Sci Rep 8(1):6220. https://doi.org/10.1038/s41598-018-24437-5 CrossRefPubMedPubMedCentral

17.

Yang S, Liu T, Cheng Y, Bai Y, Liang G (2019) Immune cell infiltration as a biomarker for the diagnosis and prognosis of digestive system cancer. Cancer Sci 110(12):3639–3649. https://doi.org/10.1111/cas.14216 CrossRefPubMedPubMedCentral

18.

Tang G, Yin W (2020) Development of an immune infiltration-related prognostic scoring system based on the genomic landscape analysis of glioblastoma multiforme. Front Oncol 10:154. https://doi.org/10.3389/fonc.2020.00154 CrossRefPubMedPubMedCentral

19.

Mony JT, Schuchert MJ (2018) Prognostic implications of heterogeneity in intra-tumoral immune composition for recurrence in early stage lung cancer. Front Immunol 9:2298. https://doi.org/10.3389/fimmu.2018.02298 CrossRefPubMedPubMedCentral

Titel: In silico analysis of the immunological landscape of pituitary adenomas
verfasst von: Jacky T. Yeung
Matthew D. Vesely
Danielle F. Miyagishima
Publikationsdatum: 31.03.2020
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2020
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03476-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Carbon ion radiotherapy for skull base chordomas and chondrosarcomas: a systematic review and meta-analysis of local control, survival, and toxicity outcomes

Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma

A matched-pair analysis comparing stereotactic radiosurgery with whole-brain radiotherapy for patients with multiple brain metastases

Intratumor injection of CCL21-coupled vault nanoparticles is associated with reduction in tumor volume in an in vivo model of glioma

Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature

High expression of estrogen receptor alpha and aromatase in glial tumor cells is associated with gender-independent survival benefits in glioblastoma patients